Gerry Broome / AP

Injections of an anti-inflammatory drug called canakinumab has been found to lower the risk of heart attack in people who have already survived one attack, according to a recent study by Brigham and Women's hospital in Boston. The drug is normally used for rare inflammatory conditions.

Why it matters: About half of all heart attacks occur in people who don't have high cholesterol levels. Researchers have suspected inflammation has a role in heart disease and this study confirms the connection. Canakinumab itself may not be useful in treating the condition because of side effects, but the finding offers another avenue for treating heart disease in people who don't respond to cholesterol-lowering statins.

The results: Out of the 10,000 patients in the study, those who were given canakinumab had a 15% lower chance of having a heart attack or stroke and a 30% lower risk of having to have an interventional procedure, such as a bypass.

The cons: Prof Martin Bennett, a cardiologist from Cambridge who did not participate in the study, told the Guardian that he his concerns were: 1.The drug (manufactured by Novartis which sponsored the study) is expensive at $200K a year. 2. It appears to increase the risk of developing a severe infection, which one out of a thousand people in the study died from 3. There was a higher risk of death among those who took the drug.

Go deeper

Updated 3 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 4:30 p.m. ET: 21,020,216 — Total deaths: 761,393— Total recoveries: 13,048,303Map.
  2. U.S.: Total confirmed cases as of 4:30 p.m. ET: 5,289,323 — Total deaths: 167,948 — Total recoveries: 1,774,648 — Total tests: 64,831,306Map.
  3. Health: CDC: Survivors of COVID-19 have up to three months of immunity Fauci believes normalcy will return by "the end of 2021" with vaccine — The pandemic's toll on mental health.
  4. Business: How small businesses got stiffed — Unemployment starts moving in the right direction.
  5. Cities: Coronavirus pandemic dims NYC's annual 9/11 Tribute in Light.
  6. Politics: Biden signals fall strategy with new ads.

Harris: "Women are going to be a priority" in Biden administration

Sen. Kamala Harris at an event in Wilmington, Del. Photo: Drew Angerer/Getty Images

In her first sit-down interview since being named Joe Biden's running mate, Sen. Kamala Harris talked about what she'll do to fight for women if elected VP, and how the Democrats are thinking about voter turnout strategies ahead of November.

What they're saying: "In a Biden-Harris administration women are going to be a priority, understanding that women have many priorities and all of them must be acknowledged," Harris told The 19th*'s Errin Haines-Whack.

Facebook goes after Apple

Illustration: Lazaro Gamio/Axios

Facebook is seeking to force a face-off with Apple over its 30% in-app purchase commission fee, which Facebook suggests hurts small businesses struggling to get by during the pandemic.

The big picture: Facebook has never publicly gone after Apple, a key strategic partner, this aggressively. Both companies face antitrust scrutiny, which in Apple's case has centered on the very fee structure Facebook is now attacking.